Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varlitinib - Array BioPharma/ASLAN Pharmaceuticals

Drug Profile

Varlitinib - Array BioPharma/ASLAN Pharmaceuticals

Alternative Names: ARRY-334543; ARRY-543; ASLAN-001; QBT-01; SPS-4370; VAR; Varlitinib tosylate

Latest Information Update: 28 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; ASLAN Pharmaceuticals; National University Hospital (Singapore)
  • Class Antineoplastics; Diamines; Oxazoles; Quinazolines; Small molecules; Thiazoles
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Biliary cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer
  • Phase II/III Gastric cancer
  • Phase II Cholangiocarcinoma; HER2 positive breast cancer
  • Phase I/II Liver cancer
  • No development reported Solid tumours; Triple negative breast cancer

Most Recent Events

  • 28 Feb 2023 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA (PO)
  • 28 Dec 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in Singapore (PO, Tablet)
  • 28 Nov 2020 No recent reports of development identified for phase-I development in Biliary-cancer(Combination therapy, Late-stage disease, Metastatic disease) in Japan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top